Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
RYTM A | $39.945 2.4% 2.34% 410K
|
Health Technology
|
| O: -0.37%
H: 1.71%
C: -1.86%
rm-718 first agonist pharmaceuticals trial
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
NAMS | $21.5 6.28% 5.91% 170K
|
n/a
|
| O: -1.03%
H: 2.61%
C: 1.91%
pharma congress trial cardiology
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
APGE | $49.77 2.32% 2.27% 280K
|
|
| O: 0.6%
H: 2.5%
C: -5.58%
apg808 first disease antibody treatment trial therapeutics
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $73.055 2.75% 2.68% 700K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12 narcolepsy symphony trial therapeutics
EVVTY DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Evolution AB (publ) Investors to Secure Counsel Before Important March 25 Deadline in Securities Class Action - EVVTY
Published: 2024-03-24 (Crawled : 16:20) - prnewswire.com
BCDRF | $4.978 -8.71% 100
|
Finance
| Email alert
Add to watchlist
SAN | $4.99 2.68% 0.0% 11M
|
Finance
| Email alert
Add to watchlist
deadline trial
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
IVVD | $2.275 3.88% 3.52% 830K
|
Manufacturing
| Email alert
Add to watchlist
vyd222 trial
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
BLTE | $37.3 8.18% 7.56% 39K
|
n/a
|
| O: -1.17%
H: 2.06%
C: 1.6%
disease japan trial submission
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
Published: 2024-03-22 (Crawled : 08:00) - biospace.com/
BPTS | $9.3 -5.3% -5.59% 9.2K
|
Manufacturing
|
| O: -8.72%
H: 13.47%
C: 6.08%
treatment
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
Published: 2024-03-22 (Crawled : 00:00) - globenewswire.com
HCM | $18.2 7.44% 6.92% 120K
|
Health Technology
|
| O: -4.4%
H: 0.97%
C: -0.73%
eslim-02 antibody anemia trial china
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
THTX | $1.29 -12.78% 8.1K
|
Health Technology
|
| O: -0.81%
H: 7.38%
C: 3.28%
cancer trial advanced
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $126.88 -0.05% 0.0% 7.5M
|
Health Technology
|
| O: -0.13%
H: 0.4%
C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Published: 2024-03-21 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9201 -4.15% -4.33% 43K
|
n/a
|
| O: 2.75%
H: 3.74%
C: -6.54%
bnc210 trial results
ROSEN, LEADING TRIAL ATTORNEYS, Encourages iRobot Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IRBT
Published: 2024-03-20 (Crawled : 20:00) - prnewswire.com
BTAFF | $30.26 44.6% 2.1K
|
Consumer Non-Durables
|
| O: -3.87%
H: 0.0%
C: -1.14%
BTI | $29.56 0.51% 0.07% 4.2M
|
Consumer Non-Durables
|
| O: -2.13%
H: 0.26%
C: -0.56%
IRBT | $6.88 2.08% 2.03% 1.4M
|
Consumer Durables
|
| O: 0.81%
H: 2.88%
C: -3.11%
AMZN S | $179.59 1.33% 1.31% 36M
|
Retail Trade
|
| O: 1.03%
H: 0.79%
C: -1.02%
corporation deadline trial
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
Published: 2024-03-20 (Crawled : 19:00) - biospace.com/
LIVN | $55.01 1.85% 1.82% 640K
|
Health Technology
|
| O: 1.81%
H: 11.57%
C: 10.5%
success positive trial study
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Published: 2024-03-20 (Crawled : 13:30) - globenewswire.com
IMMX | $2.32 8.92% 8.19% 80K
|
|
| O: -2.9%
H: 10.07%
C: 2.24%
nxc-201 cancer biopharma trial
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
FEMY | $1.34 5.51% 5.22% 280K
|
Manufacturing
|
| O: -6.5%
H: 0.53%
C: -3.74%
femaseed positive treatment topline trial
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials
Published: 2024-03-20 (Crawled : 11:00) - prnewswire.com
LH M | $207.97 2.41% 0.0% 930K
|
Health Services
|
| O: -0.32%
H: 0.29%
C: -0.45%
disease test biomarker blood trials alzheimer's
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
Published: 2024-03-19 (Crawled : 23:00) - biospace.com/
KRBP | $2.6 -90.21% 2.7K
|
Health Technology
|
| O: 19.66%
H: 30.36%
C: 1.07%
lung tumor trial results show
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
SEEL | $0.326 0.09% 0.09% 380K
|
Health Technology
|
| O: -54.24%
H: 71.43%
C: 54.76%
sls-005 update sclerosis therapeutics results study
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 870K
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.